{"id":"W2726186366","doi":"10.1200/jco.2017.35.15_suppl.5002","title":"A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; Clinical endpoint; Prednisone; Oncology; Urology; Gastroenterology; Cancer; Randomized controlled trial; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002494576,0.001852509,0.001937343,0.000532223,0.0003778418,0.001221264,0.0008313468,0.001641578,0.00770211],"category_scores_gemma":[0.00252984,0.0008227751,0.001210538,0.0004443113,0.001037516,0.001223619,0.0004693989,0.002682294,0.001354449],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008626917,"about_ca_system_score_gemma":0.001254044,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007242451,"about_ca_topic_score_gemma":0.001762368,"domain_scores_codex":[0.9992369,0.0004503198,0.00003875169,0.0001283028,0.00005476139,0.00009094329],"domain_scores_gemma":[0.9985681,0.0004178454,0.0002923122,0.0001255723,0.00008591889,0.0005102096],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9676785,0.0164636,0.0006505687,0.0002111968,0.0004233864,0.0000410426,0.00006008875,0.0003474501,0.003129553,0.00008541068,0.000453196,0.0104561],"study_design_scores_gemma":[0.8955543,0.1016803,0.001229794,0.00001357721,0.0002102265,0.00003431558,0.00002132923,0.0003220581,0.0002856845,0.0001318627,0.0005075664,0.000008945054],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9850364,0.001578931,0.001040501,0.0006515748,0.0006066679,0.007859208,0.00107902,0.0001290658,0.002018671],"genre_scores_gemma":[0.9810845,0.001325138,0.002156318,0.001383644,0.0005081498,0.007855302,0.001262687,0.00003258963,0.004391695],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00770211,"threshold_uncertainty_score":0.02576613,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1569140365483028,"score_gpt":0.5432351185979689,"score_spread":0.3863210820496661,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}